Drug General Information (ID: DDI9CZEU4S)
Drug Name			Lixisenatide		Drug Info		Chromium picolinate		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Antidiabetic Agents				Minerals And Electrolytes
Structure

Mechanism of Lixisenatide-Chromium picolinate Interaction (Severity Level: Moderate)
Increased risk of hypoglycemia Click to Show/Hide Mechanism Graph
Drug Name		Lixisenatide				Chromium picolinate
Mechanism		Antidiabetic agent				Hypoglycemic effects
Key Mechanism Factor 1
		Factor Name		Hypoglycemia
		Factor Description		Hypoglycemia is a condition in which your blood sugar (glucose) level is below the standard range. It causes irregular or rapid heartbeat, pale skin, numbness of the lips, tongue or cheeks, and sweating.
Mechanism Description		Increased risk of hypoglycemia by the combination of Lixisenatide and Chromium picolinate

Recommended Action
Management		Until further data are available, therapy with pharmacologic dosages of chromium should be administered cautiously in patients receiving insulin or other antidiabetic agents. Patients should be monitored for changes in diabetic medication requirements.

References
1	Anderson RA, cheng N, Bryden NA, et al "Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes." Diabetes 46 (1997): 1786-91. [PMID: 9356027]
2	Martin J, Wang ZQ, Zhang XH, et al. "Chromium picolinate supplementation attenuates body weight gain and increases insulin sensitivity in subjects with type 2 diabetes." Diabetes Care 29 (2006): 1826-32. [PMID: 16873787]
3	Fox GN, Sabovic Z "Chromium picolinate supplementation for diabetes mellitus." J Fam Pract 46 (1998): 83-6. [PMID: 9451374]